Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans

Bailliere's Best Practice and Research in Clinical Anaesthesiology

Volumn 14, Issue 2, 2000, Pages 261-269

  Karol, Michael D ^a   Maze, Mervyn ^b  

^a ABBOTT LABORATORIES   (United States)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Dexmedetomidine; Pharmacodynamics; Pharmacokinetics; 2 adrenergic agonist

Indexed keywords

ALFENTANIL; DEXMEDETOMIDINE; DIGOXIN; FENTANYL; ISOFLURANE; KETOROLAC; LIDOCAINE; MIDAZOLAM; PROPOFOL; ROCURONIUM; THEOPHYLLINE;

ANESTHESIA INDUCTION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; KIDNEY FAILURE; PAIN; PRIORITY JOURNAL; REVIEW;

EID: 0033742791     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1053/bean.2000.0081     Document Type: Article

References (26)

1. Crystal structures and absolute configurations of dexmedetomidine and its tosyl derivative
2. Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism
3. 2-adrenergic agonist. A review of its pharmacodynamic characteristics
4. 2-adrenoceptor agonist, reduces anesthetic requirements for patients undergoing minor gynecologic surgery
5. Influence of cardiac output on dexmedetomidine pharmacokinetics
6. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P450 2D6 (CYP2D6)
7. Effect of dexmedetomidine on propofol requirements in healthy subjects